🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

482 results for “60” Clear

  1. REGN15160 (IV)

    Regeneron UK Limited

    Healthy

    phase 1 small molecule completed

    1 trial

  2. RP-A601

    Rocket Pharmaceuticals B.V.

    PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)

    phase 1 gene therapy active

    1 trial

  3. Radiolabeled SPD602 (FBS0701, SSP-004184)

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  4. Randomised, crossover bioequivalence clinical trial of edoxaban 60 mg tablets versus edoxaban 60 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions.

    Laboratorios Tillomed Spain S.L.U

    Healthy volunteers

    phase 1 other active

    1 trial

  5. Randomized, open-label, replicated single-dose, 4-period, 2-sequence crossover study to assess the comparative bioavailability of test product Amlodipine/Valsartan/Hydrochlorothiazide 10 mg/160 mg/12.5 mg film-coated tablets to reference product Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets in healthy male and female subjects under fasting conditions.

    Lacuna Pharma Pty Ltd

    not applicable (submitted trial is bioavailability)

    phase 1 other active

    1 trial

  6. Rowasa® 4 gm/60 mL Rectal Enema

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    1 trial

  7. SHP639 (n=60)

    Takeda

    Primary Open-angle Glaucoma (POAG)

    phase 1 small molecule completed

    1 trial

  8. SLN360

    Silence Therapeutics plc

    Hyperlipidemias

    phase 1 small molecule completed

    1 trial

  9. SRP-6004

    Sarepta Therapeutics

    Limb Girdle Muscular Dystrophy

    phase 1 gene therapy terminated

    1 trial

  10. SYS6055

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory B-Cell Malignancies

    phase 1 small molecule active

    1 trial

  11. Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative bioavailability of Test Product Naproxen sodium 660 mg modified release tablets to Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fed conditions.

    Laboratorios Tillomed Spain S.L.U

    No medical condition

    phase 1 other active

    1 trial

  12. Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative bioavailability of Test Product Naproxen sodium 660 mg modified release tablets to Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fasting conditions.s.

    Laboratorios Tillomed Spain S.L.U

    Bioavailability study in healthy volunteers under fasting conditions.

    phase 1 other active

    1 trial

  13. TAEST16001

    Chongqing Precision Biotech Co., Ltd

    Liver Cancer Stage IV

    phase 1 small molecule completed

    1 trial

  14. TAEST16001 cells

    Chongqing Precision Biotech Co., Ltd

    Soft Tissue Sarcoma

    phase 1 mab active

    1 trial

  15. TD-1607

    Theravance Biopharma Ireland Umited

    Serious Infections Due to Known or Suspected Gram-positive Pathogens

    phase 1 small molecule completed

    1 trial

  16. TD-1607

    Theravance Biopharma Ireland Umited

    Infections

    phase 1 small molecule completed

    1 trial

  17. TRUQAP 200 mg film-coated tablets, Faslodex 250 mg solution for injection., TRUQAP 160 mg film-coated tablets, PACLITAXEL, IMFINZI 50 mg/mL concentrate for solution for infusion., Capecitabine Accord 500 mg film-coated tablets, Capecitabine Accord 150 mg film-coated tablets, DS-8201a, Arimidex® 1 mg film-coated tablets

    AstraZeneca AB

    Metastatic Breast Cancer

    phase 1 small molecule active

    1 trial

  18. TTP607

    vTv Therapeutics

    Advanced Cancers

    phase 1 small molecule terminated

    1 trial

  19. TV-46046

    Teva Pharma GmbH

    Contraception

    phase 1 small molecule completed

    2 trials

  20. TV-46046 - 400 mg/mL

    Teva Pharma GmbH

    Pregnancy

    phase 1 small molecule completed

    1 trial

  21. TV46017

    Teva Pharma GmbH

    Chronic Obstructive Pulmonary Disease (COPD

    phase 1 small molecule terminated

    1 trial

  22. The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment and prevention of Influenza.

    Lacuna Pharma Pty Ltd

    influenza

    phase 1 other active

    1 trial

  23. Tolvaptan 15mg or 30mg or 60mg or Placebo

    Otsuka Beijing Research Institute

    Healthy

    phase 1 small molecule completed

    1 trial

  24. UIC201602 and co-administration of UIC201601 and UIC201602

    United Therapeutics Europe Ltd

    Healthy

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources